Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Acetazolamide

FDA-approved product (tablet, oral), marketed as Acetazolamide, Diamox, Acetazolamide Sodium.

Registered studies
50+
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Acetazolamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Altitude sickness
  • Angle-closure glaucoma
  • Congestive heart failure
  • Edema
  • Epilepsy
  • Glaucoma
  • Heart failure
  • Seizure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbonic anhydrase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA14.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli17.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae10.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis85.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 6 of 6 lab records
Open Acetazolamide in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acetazolamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude

    NCT00714740 · start 2008-06

    Registered record
    Registry ID
    NCT00714740
    Conditions
    Obstructive Sleep Apnea Syndrome
    Interventions
    acetazolamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-06
    Completion
    2008-12
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea Syndrome
    Interventionacetazolamide
    PhasePhase 4
    Registry statusCompleted

  • Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones

    NCT00120731 · start 2005-07

    Registered record
    Registry ID
    NCT00120731
    Conditions
    Kidney Calculi
    Interventions
    Potassium Citrate; Acetazolamide; Diet low in oxalate and purines
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2005-07
    Completion
    2007-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Calculi
    InterventionPotassium Citrate; Acetazolamide; Diet low in oxalate and purines
    PhaseNot applicable
    Registry statusWithdrawn

  • Treatment of Orthostatic Hypotension in Autonomic Failure

    NCT00223691 · start 2002-03

    Registered record
    Registry ID
    NCT00223691
    Conditions
    Autonomic Failure; Orthostatic Hypotension
    Interventions
    Atomoxetine; Acarbose; Pyridostigmine Bromide; Yohimbine; Midodrine HCl; placebo; Modafinil; Octreotide; water intake; Diphenhydramine Hydrochloride; Ranitidine HCL; Tranylcypromine; Ergotamine/ Caffeine; Celecoxib; Pseudoephedrine; Methylphenidate; Indomethacin; Ibuprofen; Oxymetazoline 0.05% nasal solution; Bovril; Acetazolamide; Rivastigmine tartrate; Carbidopa/levodopa; Inflatable abdominal binder; inflatable abdominal binder (sham)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-03
    Completion
    2017-01
    Enrolment
    389

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutonomic Failure; Orthostatic Hypotension
    InterventionAtomoxetine; Acarbose; Pyridostigmine Bromide; Yohimbine +21 more
    PhasePhase 1
    Registry statusCompleted

  • Study of Brain Blood Flow During Induced Hypercapnia (Excess Blood Carbon Dioxide)

    NCT00001845 · start 1999-09

    Registered record
    Registry ID
    NCT00001845
    Conditions
    Healthy; Hypercapnia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1999-09
    Completion
    2004-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; Hypercapnia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Treatment of Orthostatic Intolerance

    NCT00262470 · start 1997-04

    Registered record
    Registry ID
    NCT00262470
    Conditions
    Tachycardia; Chronic Orthostatic Intolerance
    Interventions
    Acetazolamide; Atomoxetine; NO Drug; Clonidine; Entacapone; Entacapone & Propranolol; Atomoxetine & Propranolol; Indomethacin; Mecamylamine; Isosorbide Dinitrate; Melatonin; Midodrine; Modafinil; Octreotide; Placebo; Propranolol; Modafinil & Propranolol; Sertraline; IV Saline; Drinking Water; Breathing Device; memantine; Abdominal binder
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    1997-04
    Completion
    2029-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTachycardia; Chronic Orthostatic Intolerance
    InterventionAcetazolamide; Atomoxetine; NO Drug; Clonidine +19 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting